Intelligence Feed event · Policy · 2026-08-30

    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026

    Question

    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026

    Direct answer

    Cytokinetics presented late-breaking clinical trial results from its ACACIA-HCM and MAPLE-HCM studies for aficamten at the European Society of Cardiology Congress 2026. The ACACIA-HCM findings showed significant improvements in cardiac structure and diastolic function in patients with non-obstructive hypertrophic cardiomyopathy, expanding the clinical evidence base beyond obstructive HCM.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-30
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026”, revision 1, evidence through 2026-08-30. https://marketontology.com/market-events/2026-08-30/cytokinetics-presents-aficamten-phase-3-data-at-esc-congress-2026-326f9a

    POLICY
    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026
    Cytokinetics presented late-breaking clinical trial results from its ACACIA-HCM and MAPLE-HCM studies for aficamten at the European Society of Cardiology Congress 2026. The ACACIA-HCM findings showed significant improvements in cardiac structure and diastolic function in patients with non-obstructive hypertrophic cardiomyopathy, expanding the clinical evidence base beyond obstructive HCM.
    CYTK
    Impact
    71
    AUG 30
    SIG
    90%
    CYTK
    Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026
    Cytokinetics presented late-breaking clinical trial results from its ACACIA-HCM and MAPLE-HCM studies for aficamten at the European Society of Cardiology Congress 2026. The ACACIA-HCM findings showed significant improvements in cardiac structure and diastolic function in patients with non-obstructive hypertrophic cardiomyopathy, expanding the clinical evidence base beyond obstructive HCM.
    → Positive late-breaking clinical data expands the addressable commercial population for aficamten into non-obstructive HCM indications.
    Impact
    Cytokinetics presented late-breaking clinical trial results from its ACACIA-HCM and MAPLE-HCM studies for aficamten at the European Society of Cardiology Congress 2026. The ACACIA-HCM findings showed significant improvements in cardiac structure and diastolic function in patients with non-obstructive hypertrophic cardiomyopathy, expanding the clinical evidence base beyond obstructive HCM.
    Affected
    CYTK
    Transmission
    Positive late-breaking clinical data expands the addressable commercial population for aficamten into non-obstructive HCM indications.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CYTKexpanded addressable market and regulatory approval probability for aficamtenUp1-5dACACIA-HCM and MAPLE-HCM late-breaking trial presentations at ESC Congress 2026.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month